Compare Simon Property Group Inc (SPG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs Viatris Inc — how do they compare? Simon Property Group Inc trades at $227 (market cap $74.00B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Simon Property Group Inc is far larger — about 3.7× Viatris Inc's market cap, and Simon Property Group Inc pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| SPG | VTRS | |
|---|---|---|
Market Cap | $74.00B | $19.79B |
Sector | Real Estate | Health |
52-Week High | $228.70 | $17.39 |
52-Week Low | $160.68 | $8.74 |
Enterprise Value | $102.48B | $32.00B |
Dividend Yield | 3.86% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $226.79, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 earnings beating expectations at $1.48 per share versus $1.46 expected, continuing a pattern of earnings outperformance. Revenue growth has accelerated from $5.3B in 2022 to $6.4B in 2025, while net income surged to $4.63B with a remarkable 72.7% profit margin. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering.
SPG presents a compelling investment case with strong operational performance and dividend yield exceeding 4%, though current valuation metrics suggest limited upside from analyst consensus targets. Key risks include high leverage with $24.21B long-term debt and sensitivity to interest rate movements. The stock's technical overbought condition near resistance levels warrants caution despite positive earnings momentum and institutional support.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
